BusinessCRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Global Agreement on the Foundational Intellectual Property for CRISPR/Cas9 Gene Editing TechnologyBy Nasdaq OMXDec 16, 2016, 1:00 PM UTC